Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H16ClNO3.ClH |
| Molecular Weight | 342.217 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCC2=CC=CN=C2
InChI
InChIKey=MTTOJXKYQMOKBL-UHFFFAOYSA-N
InChI=1S/C16H16ClNO3.ClH/c1-16(2,21-14-7-5-13(17)6-8-14)15(19)20-11-12-4-3-9-18-10-12;/h3-10H,11H2,1-2H3;1H
Nicofibrate is an antilipidemic drug. Treatment of diabetics led to a significant reduction in plasma cholesterol and triglycerides and brought the lipoprotein picture back within the norm. Nicofibrate did not lead to significant increases in uricaemia nor to any worsening in carbohydrate tolerance. Nicofibrate may also lead to a significant drop in plasma prothrombinic activity.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60938471
Created by
admin on Mon Mar 31 22:41:28 GMT 2025 , Edited by admin on Mon Mar 31 22:41:28 GMT 2025
|
PRIMARY | |||
|
163321
Created by
admin on Mon Mar 31 22:41:28 GMT 2025 , Edited by admin on Mon Mar 31 22:41:28 GMT 2025
|
PRIMARY | |||
|
m364
Created by
admin on Mon Mar 31 22:41:28 GMT 2025 , Edited by admin on Mon Mar 31 22:41:28 GMT 2025
|
PRIMARY | Merck Index | ||
|
241-441-0
Created by
admin on Mon Mar 31 22:41:28 GMT 2025 , Edited by admin on Mon Mar 31 22:41:28 GMT 2025
|
PRIMARY | |||
|
PZE81ZT0MP
Created by
admin on Mon Mar 31 22:41:28 GMT 2025 , Edited by admin on Mon Mar 31 22:41:28 GMT 2025
|
PRIMARY | |||
|
17413-51-3
Created by
admin on Mon Mar 31 22:41:28 GMT 2025 , Edited by admin on Mon Mar 31 22:41:28 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
